Navigation Links
Onyx Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference
Date:5/6/2011

SOUTH SAN FRANCISCO, Calif., May 6, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Bank of America Merrill Lynch Health Care Conference on Thursday, May 12, 2011 at 1:30 p.m. Eastern Time (10:30 a.m. Pacific Time).  

Interested parties may access a live webcast of the presentation on our website at:

http://www.onyx-pharm.com/investors/event-calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software.  For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through May 26, 2011.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma in various settings and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ferring Pharmaceuticals to Support Great Prostate Cancer Challenge® Events Across the Country in National Effort to End Prostate Cancer
2. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
3. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
4. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
5. Amylin Pharmaceuticals to Present at the Bank of America 2011 Healthcare Conference
6. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations
7. Anadys Pharmaceuticals Reports First Quarter 2011 Financial Results and Highlights
8. Spring Bank Pharmaceuticals Awarded $3.9 Million RO1 NIH Grant to Advance Innovative Hepatitis Program
9. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
10. Savient Pharmaceuticals Submits European Marketing Authorization Application for KRYSTEXXA®
11. Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... Companion animal vaccines ... pets such as canine, avian and feline. ... such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated ... Recombinant Vaccines. Attenuated live vaccines are derived from ... have been weakend under laboratory conditions. Conjugate vaccines ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... CareSet Labs ... of e-prescribing as measured in Part D Medicare data. The dataset, called PaPR ... either using e-prescribing, faxes or paper. The PaPR (pronounced "paper") data set ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may be ... conditions and has helped many women become pregnant upon treating their diagnosis. ... and simple outpatient evaluations. We can provide the necessary information to diagnose ...
(Date:4/26/2017)... ... April 26, 2017 , ... New SUPRO® XT55 Isolated ... beverages by helping beverage manufacturers more effectively manage protein costs. “Soy protein has ... as well as more stable pricing over time. Now it’s even more relevant ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop Inc. ... Pro . This new addition to the Mirroring360 product family combines device screen ... , Mirroring360 Pro enables educators, business professionals and individuals to stream or mirror ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump challenges ... for how his administration could impact the employee benefits industry. James Slotnick, AVP, ... most likely to make it through Congress. His discussion will focus on the ...
Breaking Medicine News(10 mins):